US 2021/0267979 A1 · THERAPEUTIC AGENT FOR TREATING DIFFUSE GASTRIC CANCER

Abstract

To provide a therapeutic agent to achieve highly effect on diffuse gastric cancer typified by scirrhous gastric cancer and a therapeutic agent to achieve highly effect on cMet gene-amplified gastric cancer. The problem is solved by a therapeutic agent for treating diffuse gastric cancer containing (i) an MEK inhibitor or (ii) an MEK inhibitor and an mTOR inhibitor or a therapeutic agent for treating cMet gene-amplified gastric cancer containing (i) an MEK inhibitor or (ii) an MEK inhibitor and an mTOR inhibitor.

Claims15

Dependent claims

A method for treating diffuse gastric cancer in a patient, comprising administering to the patient an MEK inhibitor.

Dependencies are inferred from the claim text.

Facts

Application

17/058,587Filed 24 May 2019

Priority

JP 2018-10108626 May 2018

Published

2 Sep 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
A61K 31/436
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a six-membered ring having oxygen as a ring…
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Abstract

Claims15

Dependent claims

A method for treating diffuse gastric cancer in a patient, comprising administering to the patient an MEK inhibitor.

Dependencies are inferred from the claim text.

Therapeutic agent for treating diffuse gastric cancer

Life of this patent

Abstract

Claims15

Therapeutic agent for treating diffuse gastric cancer

Life of this patent

Abstract

Claims15